HROW
Harrow, Inc. Health Care Pharmaceutical Preparations Russell 3000
$28.24Close
$1.1BMarket cap
$27.24 – $54.8052-week range
Nov 9, 2026Next report · after the close
Highlights
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 9 · weaker than 91% of stocks over 12 months
- Far from its high 48% below its 52-week high
- Distribution down-day volume 2.1× up-day volume over 50 sessions
- Earnings shrinking EPS −460% year on year
- Results soon Nov 9, 2026, in 8 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
48%
1wk
down 0.7%
price change
1mo
down 8.3%
price change
12-month return
down 25%
market up 11% ·
its own down 34%
F-score
6 / 9
Mixed
Altman Z
2.55
Moderate risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
20.0×
price / book
Earnings yield
up 2.5%
EBIT / enterprise value
Cheaper than
35%
of the market · expensive
Revenue growth
up 36%
year on year
EPS growth
down 460%
latest quarter
Sales growth
up 11%
latest quarter · +18 pts
ROE
down 8%
return on equity
Free cash margin
up 16%
$43.0M FCF
D/E
4.77
long-term debt / equity
Net debt / EBITDA
5.6×
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- issued more shares
- gross margin narrowed
- generating cash from operations
- profitability improving
- profits backed by cash
- reduced long-term debt
- short-term liquidity improved
- assets working harder
Repair signals
- FCF turned positive ($-24M → $43M)
Trade setup
ATR%
4.8%
$1.34 a day · 2×ATR $25.55
RS
9 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
0.6×
vs 50-day average
Up/down volume
0.49
50 sessions
Implied move
—
no option chain · report Nov 9, 2026
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Heavily indebted Net debt is 5.6 times EBITDA — roughly 6 years of earnings before interest, tax and depreciation to repay borrowings in full.
- Shareholders diluted The share count rose 4.5% over the year, from 36m to 37m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 10, 2026
Results reaction
Aug 10, 2026-2% vs market2 sessions after results
Financials
- Gross 75%
- Net -2%
- Free cash 16%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $48.9M | $72.5M | $88.6M | $130.2M | $199.6M | $272.3M |
| Gross margin | 70% | 75% | 71% | 70% | 75% | 75% |
| Operating income | $385,000 | $1.6M | $1.9M | $431,000 | $8.8M | $30.5M |
| Net income | -$3.4M | -$18.0M | -$14.1M | -$24.4M | -$17.5M | -$5.1M |
| Net margin | -7% | -25% | -16% | -19% | -9% | -2% |
| Earnings per share | -$0.13 | -$0.67 | -$0.51 | -$0.75 | -$0.49 | -$0.14 |
| Free cash flow | -$2.0M | $3.3M | -$892,000 | $2.4M | -$23.8M | $43.0M |
| Free cash margin | -4% | 5% | -1% | 2% | -12% | 16% |
| Cash | $4.1M | $42.2M | $96.3M | $74.1M | $47.2M | $72.9M |
| Long-term debt | $20.0M | $103.0M | $151.8M | $246.7M | $262.7M | $250.0M |
| Shareholders' equity | $27.2M | $11.3M | $27.6M | $70.8M | $69.7M | $52.4M |
| Shares outstanding | 25.75m | 26.90m | 29.90m | 35.17m | 35.62m | 37.23m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 10, 2026 | Quarterly ↗ | Jun 30, 2026 | 41d |
| May 11, 2026 | Quarterly ↗ | Mar 31, 2026 | 41d |
| Mar 2, 2026 | Annual ↗ | Dec 31, 2025 | 61d |
| Nov 10, 2025 | Quarterly ↗ | Sep 30, 2025 | 41d |
| Aug 11, 2025 | Quarterly ↗ | Jun 30, 2025 | 42d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Mar 27, 2025 | Annual ↗ | Dec 31, 2024 | 86d |
| Nov 14, 2024 | Quarterly ↗ | Sep 30, 2024 | 45d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 13, 2024 | Quarterly ↗ | Mar 31, 2024 | 43d |
| Mar 19, 2024 | Annual ↗ | Dec 31, 2023 | 79d |
| Nov 13, 2023 | Quarterly ↗ | Sep 30, 2023 | 44d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 5, 2026 | Material agreement · Acquisition or disposal · Regulation FD ↗ |
| Sep 4, 2026 | Director or officer change ↗ |
| Aug 10, 2026 | Results · Regulation FD ↗ |
| Aug 6, 2026 | Material agreement · Regulation FD ↗ |
| Jun 22, 2026 | Shareholder vote ↗ |
| Jun 3, 2026 | Regulation FD ↗ |
| May 11, 2026 | Results · Regulation FD ↗ |
| Mar 27, 2026 | Material agreement · New obligation · Other events ↗ |
| Mar 24, 2026 | Other events ↗ |
| Mar 24, 2026 | Other events ↗ |
| Mar 10, 2026 | Regulation FD ↗ |
| Mar 2, 2026 | Results · Regulation FD ↗ |